Emergent Biosolutions EBS Class of Warrant or Right, Outstanding

Other financials

Revenue$156.1M-29.7%

Gross profit$84.1M-37.1%

Operating income$10.5M-79.0%

Net income$6.8M-90.0%

EPS (diluted)$0.07-94.1%

Cash & equivalents$161.5M+5.7%

Total debt$584.6M-13.1%

Total equity$523.1M-5.4%

Total assets$1.3B-7.4%

Operating cash flow-$33.8M-202%

CapEx$2.4M-33.3%

Free cash flow-$36.2M-145%

Market cap$411.74M+22.0%

Enterprise value$834.84M-2.6%

P/E3.6×—

P/S0.6×+0.3×

Gross margin54.2%+19.0pp

Operating margin15%+10.3pp

Net margin9.6%+5.8pp

FCF margin20.8%—

Return on equity13.9%+8.1pp

Debt / equity1.1×-0.1×

Current ratio4.3×-2.0×

Reported directly by Emergent Biosolutions in its filing.

Tagged under the XBRL concept us-gaap:ClassOfWarrantOrRightOutstanding.

The official record: Emergent Biosolutions’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is Emergent Biosolutions's class of warrant or right, outstanding?: Emergent Biosolutions (EBS) reported class of warrant or right, outstanding of $2.5M in Q1 2026.
How has Emergent Biosolutions's class of warrant or right, outstanding changed year-over-year?: Emergent Biosolutions's class of warrant or right, outstanding decreased by 0.0% year-over-year, from $2.5M to $2.5M.